| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Groupe Hôspitalier Cochin, Assistance Publique Hôpitaux de Paris, Faculté Cochin Port-Royal, Université Paris, Paris, and 2 Boehringer Ingelheim France, Reims, France.
CORRESPONDENCE: D. Dusser, Service de Pneumologie, Hôpital Cochin, 27 Rue du Faubourg Saint Jacques, 75679 Paris, Cedex 14, France. Fax: 33 146338253. E-mail: daniel.dusser{at}cch.aphp.fr
Keywords: Chronic obstructive pulmonary disease, exacerbations, health resource utilisation, peak expiratory flow, tiotropium
Received: May 30, 2005
Accepted December 6, 2005
This randomised, double-blind, parallel-group, 1-yr study compared the effect of tiotropium 18 µg once daily (n = 500) and placebo (n = 510) on exacerbations, associated health resource use (HRU) and airflow limitation in chronic obstructive pulmonary disease (COPD) patients.
The mean±SD number of exacerbations during the past year was 2.14±1.40, the mean weekly morning peak expiratory flow (PEF) was 259.6±96.1 L·min–1 and the mean forced expiratory volume in one second (FEV1) was 1.37±0.45 L. Tiotropium significantly delayed the time to first exacerbation by
In conclusion, tiotropium reduced exacerbations and associated health resource use, and improved airflow over 1 yr in chronic obstructive pulmonary disease patients.
100 days, reduced the proportion of patients experiencing more than one exacerbation by 17%, and decreased the number of exacerbations by 35% and exacerbation days by 37% versus placebo. Tiotropium also decreased HRU versus placebo, as indicated by the significant reductions in the use of concomitant respiratory medications, antibiotics and oral steroids, and the number of unscheduled physician contacts. Mean weekly morning PEF improved significantly with tiotropium versus placebo from week 1 until the end of the study. At the end of the study, tiotropium significantly improved trough (pre-dose) FEV1, forced vital capacity, slow vital capacity and inspiratory capacity versus placebo.
This article has been cited by other articles:
|
|
 |
|
  K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD Chest, August 1, 2008; 134(2): 255 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa, P. Ernst, K. L. Vandemheen, and S. D. Aaron Methodological issues in therapeutic trials of COPD Eur. Respir. J., May 1, 2008; 31(5): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. MacNee Update in Chronic Obstructive Pulmonary Disease 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oba Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease? Ann Intern Med, April 15, 2008; 148(8): 626 - 626. [Full Text] [PDF]
|
|
|
|
 |
|
 S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials Thorax, February 1, 2008; 63(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vijayasaratha and R. A. Stockley Reported and Unreported Exacerbations of COPD: Analysis by Diary Cards Chest, January 1, 2008; 133(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T. J. Wilt, S. Weinberger, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, November 6, 2007; 147(9): 633 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Anzueto, S. Sethi, and F. J. Martinez Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 554 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Powrie, T. M. A. Wilkinson, G. C. Donaldson, P. Jones, K. Scrine, K. Viel, S. Kesten, and J. A. Wedzicha Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD Eur. Respir. J., September 1, 2007; 30(3): 472 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rodriguez-Roisin Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Eur. Respir. Rev., December 1, 2006; 15(99): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R G Barr, J Bourbeau, C A Camargo, and F S F Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax, October 1, 2006; 61(10): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
